GH Research's (GHRS) Market Outperform Rating Reaffirmed at JMP Securities

GH Research (NASDAQ:GHRS - Get Free Report)'s stock had its "market outperform" rating reaffirmed by analysts at JMP Securities in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $39.00 price target on the stock. JMP Securities' target price indicates a potential upside of 232.74% from the company's current price.

GHRS has been the topic of several other reports. Cantor Fitzgerald initiated coverage on shares of GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price objective on the stock. Stifel Nicolaus boosted their price target on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Guggenheim decreased their price target on shares of GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Wall Street Zen downgraded shares of GH Research from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, GH Research has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $11.72 on Tuesday. GH Research has a one year low of $6.00 and a one year high of $20.50. The stock has a market capitalization of $609.84 million, a price-to-earnings ratio of -15.01 and a beta of 0.97. The company has a 50-day simple moving average of $11.10 and a 200-day simple moving average of $10.55.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.42. As a group, research analysts forecast that GH Research will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in GH Research in the 4th quarter valued at about $44,000. Palumbo Wealth Management LLC purchased a new stake in shares of GH Research in the first quarter valued at $142,000. XTX Topco Ltd purchased a new position in shares of GH Research during the first quarter valued at $169,000. Two Sigma Investments LP acquired a new position in GH Research during the fourth quarter valued at $117,000. Finally, Millennium Management LLC acquired a new stake in GH Research during the 4th quarter worth about $145,000. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.